Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2013 Oct 15;12(12):10.1158/1535-7163.MCT-13-0547. doi: 10.1158/1535-7163.MCT-13-0547

Figure 3. A novel HER/VEGF signature correlates with poor overall survival in high-grade serous ovarian cancer patient tumors.

Figure 3

(A) Heatmap depicting unsupervised hierarchical clustering of high-grade, late stage, serous ovarian tumors from the TCGA using a proangiogenic (PA) gene signature. (B) Kaplan Meier analysis of PA tumors stratified by ErbB2 expression into PA/ErbB2 High (dotted line) vs. PA/ErbB2 Low (solid line) and confirmed in four independent cohorts (identified by TCGA or GEO accession number).